Chia-Jung Kuo

Chia-Jung Kuo

Auto-generated profile, based on publicly available information

Chia-Jung Kuo

Department of Gastroenterology and Hepatology Chang Gung Memorial Hospital Taoyuan Linkou Taiwan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
MMMing-Jung Meng
Ming-Jung Meng
CKChia-Jung Kuo
Chia-Jung Kuo
MLMing-Wei Lai
Ming-Wei Lai
Cheng-Hsun ChiuCheng-Hsun Chiu
Cheng-Hsun Chiu
MSMing-Yao Su
Ming-Yao Su
PLPuo-Hsien Le
Puo-Hsien Le
Background: Refractory inflammatory bowel disease (IBD) remains challenging despite the availability of various biologics. Advanced combination therapy (ACT) with biologics and Upadacitinib (UPA), a rapid-onset oral selective Janus kinase inhibitor, has shown promise in managing refractory IBD. However, its use in Asia has not been explored. This study aims to fill that gap by providing data from Taiwan. Materials and Methods: This retrospective study included refractory IBD patients who received ACT with biologics and UPA, followed up at the Chang Gung Inflammatory Bowel Disease Center from July 2020 to August 2024. Patients were assessed for clinical response and remission at weeks 4, 12, and 24. Safety profiles were monitored throughout the follow-up period to evaluate the risk of adverse events. Results: Sixteen refractory IBD patients were enrolled. The median disease duration was 4.5 years [IQR 2.25– 9.50]. The most common regimen was Ustekinumab plus UPA (63%). Clinical response rates at weeks 4, 12, and 24 were 88%, 83%, and 100%, respectively, while remission rates were 31%, 50%, and 80%. One patient (6.25%) experienced a minor adverse event (acne), with no major events like herpes zoster reactivation or major cardiac complications. Conclusion: This is the first study in Asia to demonstrate that UPA-based ACT is both effective and safe in treating refractory IBD. However, the limitations of this retrospective, single-center study with a relatively small sample size highlight the need for future larger-scale, multi-center prospective studies to confirm these findings, identify predictors of treatment response, and evaluate long-term outcomes.

5 September 2022 in Materials Science and Engineering: A
Verified
Journal Article
Open access
PJPéter Jenei
Péter Jenei
CKCsilla Kádár
Csilla Kádár
ÁSÁbel Szabó
Ábel Szabó
SHSun–Mao Hung
Sun–Mao Hung
CKChia–Jung Kuo
Chia–Jung Kuo
Jenő GubiczaJenő Gubicza
Jenő Gubicza

17 March 2025 in The Kaohsiung Journal of Medical Sciences
Verified
Journal Article
Open access
PLPuo-Hsien Le
Puo-Hsien Le
Chyi-Liang ChenChyi-Liang Chen
Chyi-Liang Chen
CKChia‐Jung Kuo
Chia‐Jung Kuo
PYPai-Jui Yeh
Pai-Jui Yeh
CCChien-Chang Chen
Chien-Chang Chen
Cheng-Hsun ChiuCheng-Hsun Chiu
Cheng-Hsun Chiu
Clostridioides difficile infection (CDI) worsens the prognosis of patients with inflammatory bowel disease (IBD). This retrospective cohort study aimed to evaluate the risk factors, clinical manifestations, and outcomes of CDI in hospitalized patients with IBD, including those with toxin A/B results between April 2007 and April 2021. Patients were classified into the CDI and control groups. Patients with IBD and recurrent or refractory CDI underwent fecal microbiota transplantation (FMT). A total of 144 inpatients with IBD—45 in the CDI group and 99 in the control group—were analyzed. The incidence of CDI in inpatients with IBD was 31%. The Risk factors for CDI included longer IBD duration, biological therapy failure, and biological use. More patients in the CDI group presented with abdominal pain (77.8% vs. 55.6%, p = 0.011). In the antibiotic treatment‐only group, the symptom improvement rate was 60.7% (17/28), the microbiological cure rate was 89.3% (25/28), and the overall success rate was 71.4% (20/28). After antibiotic treatment and FMT, 71.4% (10/14) of the patients tested negative for CDI, and 64.3% (9/14) had improved clinical symptoms. CDI led to more hospitalizations (median two times [range 0–12] vs. median one time [range 0–19], p = 0.008), a lower steroid‐free remission rate (46.7% vs. 67.7%, p = 0.017), and higher Mayo scores (median 5 points [range 2–12] vs. median 3 points [range 0–12]). Patients who received FMT had fewer hospitalizations and fewer IBD‐related complications during follow‐up than those who received antibiotics alone. FMT should be considered in patients with IBD with refractory or recurrent CDI to improve clinical outcomes.